Sierra Oncology, Inc. (NASDAQ: SRRA) is focussed on creating novel targeted therapies that address large unmet needs in rare forms of cancer. The Company’s lead product candidate is momelotinib, a selective and orally bioavailable JAK1, JAK2 and ACVR1/ALK2 inhibitor being developed for the treatment of...
Celsion Corporation (NASDAQ: CLSN) announced the receipt of a Fast-Track Designation from the U.S. Food and Drug Administration (FDA) for GEN-1, its DNA-mediated interleukin-12 (IL-12) immunotherapy that is currently undergoing Phase II trials for the treatment of advanced ovarian cancer. The candidate is an IL-12...
Sciatica also known as lumbosacral radiculopathy or radicular leg pain is a chronic pain condition that affects approximately 1 in 20 adults each year with over 40% of people likely to suffer from sciatica during their lifetime. A herniated vertebral disc is the most common...
PhaseBio’s (NASDAQ: PHAS), PB2452 is the new drug on the block, which has received a breakthrough therapy status from the FDA in April 2019. The company’s stock rose by almost 32%, on the day it announced the news. It acts as a reversal agent for...
TG Therapeutics (NASDAQ: TGTX), a clinical stage company that is leading the innovation bandwagon in the field of novel therapies for B-cell malignancies and autoimmune diseases has had a great run at the stock market so far this year. Its stocks have almost doubled in 2019 owing...
An estimated 2,400 – 2,800 new incidence of Mesothelioma occurs each year in the U.S alone, according to an estimate by the Centers for Disease Control and Prevention (CDC). The disease caused by exposure to asbestos will likely affect 20 million people worldwide according to a...
